# TAK-438 - Safety, Blood Levels & Effects of Repeated Doses

> **NCT02141711** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 48 (actual)

## Conditions studied

- Erosive Esophagitis(EE)
- Gastroesophageal Reflux Disease (GERD)

## Interventions

- **DRUG:** TAK-438
- **DRUG:** TAK-438 Placebo

## Key facts

- **NCT ID:** NCT02141711
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02141711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02141711, "TAK-438 - Safety, Blood Levels & Effects of Repeated Doses". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02141711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*